Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a fixed-dose combination of dexamethasone, a synthetic corticosteroid with potent anti-inflammatory and immunosuppressant properties, and iron isomaltoside, an intravenous iron preparation used to treat iron deficiency anemia. Dexamethasone acts by binding to the glucocorticoid receptor, modulating gene expression to suppress inflammation and immune responses[4][5][9]. Iron isomaltoside consists of iron(III) complexed with the carbohydrate isomaltoside 1000; it enables controlled release of bioavailable iron for erythropoiesis and replenishment of body stores[2][3]. The combination may be used in clinical scenarios where both anti-inflammatory effects and rapid correction of anemia are required (e.g., certain pregnancy complications or chronic diseases), though no widely marketed product under this exact combination name exists. Each component has established uses individually.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + iron isomaltoside.